BFLY — Butterfly Network, Inc.

Butterfly Network Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $26.5 million, a 25% year-over-year increase.
• Gross Margin: 69%, up from 63% in the prior year.
• Adjusted EBITDA Loss: $6.1 million, improved from a loss of $9.1 million in Q1 2025.
• Cash Position: $138 million in cash and cash equivalents, with a cash burn of $12.5 million in the quarter, down from $14.7 million year-over-year.
• Core Revenue: $20.8 million (10% increase), driven by higher sales of the iQ3 devices.
• Embedded Revenue: $5.7 million (147% increase), largely due to the Midjourney partnership.

2. Strategic Updates and Business Highlights:

• Butterfly Network is focusing on becoming a leader in point-of-care ultrasound (POCUS) and is experiencing a digital transformation in imaging through AI and semiconductor technology.
• The company received FDA clearance for a blind sweep AI tool to determine fetal gestational age, enhancing its product offering and potential market reach.
• The Butterfly Garden platform now includes 30 partners, with several receiving FDA clearance for their applications.
• The Compass AI software is gaining traction, with a significant enterprise deal closed in Q1 and a growing pipeline.
• The Home and Community Care initiative is set to launch commercially in 2026, aiming to reduce hospital visits and improve patient outcomes through AI diagnostics.

3. Forward Guidance and Outlook:

• Q2 2026 Revenue Guidance: Expected between $27 million and $31 million, representing a year-over-year increase of approximately 24% at the midpoint.
• Full Year 2026 Revenue Guidance: Reaffirmed at $117 million to $121 million, a 20% to 24% increase over 2025.
• Adjusted EBITDA Loss Guidance: Expected between $21 million and $25 million for the full year, reflecting ongoing investments in growth areas.

4. Bad News, Challenges, or Points of Concern:

• The company is navigating a complex global macroeconomic environment, including geopolitical tensions and tariffs, though impacts have been minor thus far.
• The ongoing need for regulatory approvals and the challenge of integrating new technologies into existing healthcare systems remain potential hurdles.
• The reliance on partnerships for growth in the Embedded business could pose risks if these relationships do not materialize as expected.

5. Notable Q&A Insights:

• The company is optimistic about its partnerships with medical schools, anticipating strong growth in the second quarter.
• There is a significant increase in the pipeline for Compass AI enterprise deals, suggesting potential for substantial revenue contributions in the near future.
• The Home and Community Care initiative is expected to show revenue contributions in the second half of 2026, with plans for expansion across states in 2027.
• The FDA's recognition of Butterfly's AI tool is seen as a competitive advantage and may stimulate interest from partners in developing similar applications.

Overall, Butterfly Network is experiencing strong growth and is strategically positioned for future expansion, despite facing challenges in the broader economic landscape.